Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production

Jean Francois H. Geschwind, Young H. Ko, Michael S. Torbenson, Carolyn Magee, Peter L. Pedersen

Research output: Contribution to journalArticlepeer-review

Abstract

Most types of cancer are difficult to eradicate and some, like liver carcinomas, are almost always fatal. Significantly, we report here that direct intraarterial delivery of 3-bromopyruvate (3-BrPA), a potent inhibitor of cell ATP production, to liver-implanted rabbit tumors, inflicts a rapid, lethal blow to most cancer cells therein. Moreover, systemic delivery of 3-BrPA suppresses "metastatic" tumors that arise in the lungs. In both cases, there is no apparent harm to other organs or to the animals. Thus, intraarterial delivery of agents like 3-BrPA directly to the site of the primary tumor, followed by systemic delivery only when necessary, may represent a powerful new strategy for arresting the growth of liver and other cancers while minimizing toxic side effects.

Original languageEnglish (US)
Pages (from-to)3909-3913
Number of pages5
JournalCancer Research
Volume62
Issue number14
StatePublished - Jul 15 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production'. Together they form a unique fingerprint.

Cite this